 |
2008
OMIG, Abstract 13
OMIG
Main Page | 2008 Abstracts | < Previous| Next >
Comparison of In Vitro Susceptibilities of Gatifloxacin and Moxifloxacin Against Gram Positive Cocci Isolated from Ocular Infections.
Ashok Kumar Reddy1, PhD, Prashant Garg2, MD, Md. Rajeeb Alam3, DO, Usha Gopinathan11 PhD. Savitri Sharma1, MD. Sannapaneni Krishnaiah, MPS.
1.Jhaveri Microbiology Centre, Hyderabad Eye Research Foundation, L.V.Prasad Eye Institute, Hyderabad, India.
2.Cornea and Anterior Segment services, L.V.Prasad Eye Institute, Hyderabad, India.
3.Cornea and Anterior Segment Services, M.A.I. Eye Institute and Hospital, Farmgate, Dhaka, Bangladesh.
4.Internatoional Center for Advancement of Rural Eye Care, L.V.Prasad Eye Institute, Hyderabad, India.
Purpose:To compare the invitro susceptibilities of gatifloxacin and moxifloxacin against Gram positive cocci isolated from ocular infections.
Methods:A retrospective review of microbiology records at L.V.Prasad Eye Institute, Hyderabad, India, identified 787 Gram positive cocci isolated from different ocular infections between January 2005 to May 2008. Antibiotic susceptibility of the isolates was determined by using Kirby Bauer disc diffusion method to ciprofloxacin, ofloxacin, gatifloxacin and moxifloxacin.
Results:Out of 787 isolates, 147 (18.7%) were staphylococcus aureus, 279 (35.2%) were coagulase negative Staphylocci, 357 (45.4%) were Streptococcus pneumoniae and 4 (0.4%) were other streptococcus species. Of all the four quinolones tested, gatifloxacin showed highest susceptibility (85.6%) followed by ofloxacin (65.6%), moxifloxacin (63.9%) and ciprofloxacin (60.5%). Thirty three (4.2%) of 787 isolates were resistant to all the four fluoroquinolones. Staphylococcus aureus and coagulase negative Staphylococcus isolates that were resistant to ciprofloxacin and ofloxacin were most susceptible to gatifloxacin. Streptococcus pneumoniae were more susceptible to gatifloxacin, oflaxacin, and ciprofloxacin than moxifloxacin.
Conclusions:Gatifloxacin is more potent than moxifloxacin against Gram positive cocci isolated from ocular infections.
Disclosure code: N
|
 |
|
